Search research articles
Contact Us
Filters
Showing results (221-230 of 266) with videos related to
Page
of 27
Sort By:
The Journal of Clinical Investigation
|
February 5, 2020
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target
Zachary T Freeman, Thomas R Nirschl, Daniel H Hovelson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2022
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
Emerson A Lim, Johanna C Bendell, Gerald S Falchook, et al.
The American Journal of Pathology
|
March 27, 2018
Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer
Michael C Haffner, Gunes Guner, Diana Taheri, et al.
Cancer Cell
|
November 3, 2023
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer
Jessica E Hawley, Aleksandar Z Obradovic, Matthew C Dallos, et al.
Cancer Research
|
December 22, 2011
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape
Seng-Ryong Woo, Meghan E Turnis, Monica V Goldberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2016
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M Beer, Eugene D Kwon, Charles G Drake, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2015
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
David F McDermott, Charles G Drake, Mario Sznol, et al.
Scientific Reports
|
January 16, 2024
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Nirmish Singla, Thomas R Nirschl, Aleksandar Z Obradovic, et al.
Cancer Immunology Research
|
February 23, 2018
Quantitative Analysis of Immune Infiltrates in Primary Melanoma
Robyn D Gartrell, Douglas K Marks, Thomas D Hart, et al.
Oncotarget
|
May 4, 2018
PD-L1 expression in medulloblastoma: an evaluation by subgroup
Allison M Martin, Christopher J Nirschl, Magda J Polanczyk, et al.
Page
of 27
Search research articles
Search
Showing results (221-230 of 266) with videos related to
Sort By:
Page
of 27
The Journal of Clinical Investigation
|
February 5, 2020
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target
Zachary T Freeman, Thomas R Nirschl, Daniel H Hovelson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2022
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
Emerson A Lim, Johanna C Bendell, Gerald S Falchook, et al.
The American Journal of Pathology
|
March 27, 2018
Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer
Michael C Haffner, Gunes Guner, Diana Taheri, et al.
Cancer Cell
|
November 3, 2023
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer
Jessica E Hawley, Aleksandar Z Obradovic, Matthew C Dallos, et al.
Cancer Research
|
December 22, 2011
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape
Seng-Ryong Woo, Meghan E Turnis, Monica V Goldberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2016
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M Beer, Eugene D Kwon, Charles G Drake, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2015
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
David F McDermott, Charles G Drake, Mario Sznol, et al.
Scientific Reports
|
January 16, 2024
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Nirmish Singla, Thomas R Nirschl, Aleksandar Z Obradovic, et al.
Cancer Immunology Research
|
February 23, 2018
Quantitative Analysis of Immune Infiltrates in Primary Melanoma
Robyn D Gartrell, Douglas K Marks, Thomas D Hart, et al.
Oncotarget
|
May 4, 2018
PD-L1 expression in medulloblastoma: an evaluation by subgroup
Allison M Martin, Christopher J Nirschl, Magda J Polanczyk, et al.
Page
of 27